Maridea Wealth Management LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

Maridea Wealth Management LLC acquired a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 27,281 shares of the biopharmaceutical company’s stock, valued at approximately $724,000.

A number of other hedge funds have also made changes to their positions in the stock. DnB Asset Management AS boosted its stake in Pfizer by 22.9% during the fourth quarter. DnB Asset Management AS now owns 1,893,396 shares of the biopharmaceutical company’s stock valued at $50,232,000 after buying an additional 352,515 shares in the last quarter. Slagle Financial LLC boosted its position in shares of Pfizer by 6.1% during the 4th quarter. Slagle Financial LLC now owns 73,628 shares of the biopharmaceutical company’s stock valued at $1,953,000 after purchasing an additional 4,264 shares in the last quarter. denkapparat Operations GmbH acquired a new position in shares of Pfizer in the 4th quarter worth approximately $551,000. Orion Portfolio Solutions LLC raised its holdings in shares of Pfizer by 5.3% in the 4th quarter. Orion Portfolio Solutions LLC now owns 582,270 shares of the biopharmaceutical company’s stock worth $15,448,000 after purchasing an additional 29,552 shares in the last quarter. Finally, Providence Capital Advisors LLC lifted its stake in Pfizer by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock valued at $3,034,000 after purchasing an additional 409 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.20 on Friday. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The business has a fifty day simple moving average of $26.06 and a 200 day simple moving average of $26.94. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $142.93 billion, a price-to-earnings ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter last year, the firm earned $0.10 earnings per share. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Citigroup cut their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Bank of America reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.